Connect your AI

JBIO JBIO Change in Other Assets

Change in Other Assets at other companies

Travere Therapeutics, Inc.TVTX

$6.38M+282%

Vera TherapeuticsVERA

$5.14M-12.5%

AnaptysBio, Inc.ANAB

-$1.5M-183%

Avalo TherapeuticsAVTX

-$228K+90.9%

Cullinan Therapeutics, Inc.CGEM

$662K+138%

Vor BiopharmaVOR

$6.36M+2,653%

Other financials

Income statement

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: JBIO’s 10-Q, filed November 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about JBIO's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is JBIO's change in other assets?: JBIO (JBIO) reported change in other assets of $1.86M in Q3 2025.
How has JBIO's change in other assets changed year-over-year?: JBIO's change in other assets increased by 764.7% year-over-year, from $215K to $1.86M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.